Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”) today provided a third quarter 2026 business update for its wholly owned subsidiary, CNSide Diagnostics, LLC, highlighting gross payer billings, progress on Medicare coverage of its Tumor Cell Enumeration Test (TCE Test) and the expansion of the CNSide testing menu.

  • Payer Billing: In Q3 2026, CNSide billed 222 tests representing $1.55 million of unaudited gross billings, with initial cash collections anticipated in Q4 2026